纤维蛋白原γ链肽包被ADP脂质体对体外循环后凝血病影响的体外研究:基于患者血液
本研究纳入10例体外循环术后接受血小板输注的患者,在切皮时、体外循环结束及血小板输注后即刻三个时间点采集血样,与H12-ADP脂质体或磷酸盐缓冲液(PBS)孵育后评估凝血能力、血小板活化及血小板-白细胞聚集。结果显示各时间点H12-ADP脂质体组与PBS组在上述指标上均无差异。结论认为H12-ADP脂质体未引起异常凝血、血小板活化或血小板-白细胞聚集,提示或可安全用于此类患者。
要点
- 体外实验中H12-ADP脂质体未增加体外循环术后患者血液的凝血能力。
- H12-ADP脂质体未引起血小板活化或血小板-白细胞聚集增加。
- 作者认为该脂质体或可安全用于此类患者,但尚需进一步研究确保人体安全性。
核心结论
- H12-ADP脂质体未在体外循环术后接受血小板输注患者的血液中引起异常凝血、血小板活化或血小板-白细胞聚集。
- 作者认为这些结果提示H12-ADP脂质体或可安全用于此类患者,在出血部位提供止血而不引起明显不良反应。
- 作者指出尚需进一步研究以确保在人体的稳健安全性。
研究设计与样本
- 体外研究,纳入10例体外循环术后接受血小板输注的患者。
- 血样采集于三个时间点:切皮时、体外循环结束时、血小板输注后即刻。
- 血样与H12-ADP脂质体或磷酸盐缓冲液(PBS,对照)孵育后评估凝血、血小板活化及血小板-白细胞聚集。
主要发现
- 各时间点H12-ADP脂质体孵育血样与PBS孵育血样在凝血能力上无差异。
- 各时间点两组在血小板活化程度上无差异。
- 各时间点两组在血小板-白细胞聚集上无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出尚需进一步研究以确保H12-ADP脂质体在人体的稳健安全性。
- 本研究为体外研究,尚未在人体内验证其高凝潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrinogen γ-chain peptide-coated, adenosine 5'-diphosphate (ADP)-encapsulated liposomes (H12-ADP-liposomes) are potent hemostatic adjuvants that promote platelet thrombi formation at bleeding sites. Although we have reported the efficacy of these liposomes in a rabbit model of cardiopulmonary bypass coagulopathy, we are yet to address the possibility of their hypercoagulative potential, especially in human beings. OBJECTIVES: Considering its future clinical applications, we herein investigated the safety of using H12-ADP-liposomes in vitro using blood samples from patients who had received platelet transfusion after cardiopulmonary bypass surgeries. METHODS: Ten patients receiving platelet transfusions after cardiopulmonary bypass surgery were enrolled. Blood samples were collected at the following 3 points: at the time of incision, at the end of the cardiopulmonary bypass, and immediately after platelet transfusion. After incubating the samples with H12-ADP-liposomes or phosphate-buffered saline (PBS, as a control), blood coagulation, platelet activation, and platelet-leukocyte aggregate formation were evaluated. RESULTS: Patients' blood incubated with H12-ADP-liposomes did not differ from that incubated with PBS in coagulation ability, degree of platelet activation, and platelet-leukocyte aggregation at any of the time points. CONCLUSION: H12-ADP-liposomes did not cause abnormal coagulation, platelet activation, or platelet-leukocyte aggregation in the blood of patients who received platelet transfusion after a cardiopulmonary bypass. These results suggest that H12-ADP-liposomes could likely be safely used in these patients, providing hemostasis at the bleeding sites without causing considerable adverse reactions. Future studies are needed to ensure robust safety in human beings.
引用
- Ishida O, Hagisawa K, Yamanaka N, et al. In vitro study on the effect of fibrinogen γ-chain peptide-coated ADP-encapsulated liposomes on postcardiopulmonary bypass coagulopathy using patient blood. J Thromb Haemost. 2023. PMID: 36990156. doi:10.1016/j.jtha.2023.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。